There are plenty of reasons why this growing biotech company should be on your watchlist including an $18.70 price target!The biotech space is anticipated for a big rebound this year and one company that looks well-positioned to stand out is BioStem Technologies, Inc. (OTCQB: BSEM). In the last year, the company's share price has moved from around $1 to over $9. It's evident that Wall Street is paying attention to this biotech company's game-changing offerings for the global wound care market. The company is making waves for its focus on harnessing elements of perinatal tissue derived from the human placenta for manufacturing structural tissue allografts to heal wounds. The market for improved wound care products is growing exponentially. In terms of revenue, the global wound care market in terms of revenue was estimated to be worth $20.8 billion in 2022 and is poised to reach $27.2 billion by 2027, growing at a CAGR of 5.4% from 2022 to 2027. It wasn't that long ago that Zack's Small Cap Research had increased its price target on the stock given the explosive Q3 earnings that were reported and recently reiterated that the company may be undervalued! Zack's has increased its price target on BioStem Technologies, Inc. (OTCQB: BSEM) to $18.70! The price increase comes shortly after the company released some preliminary and unaudited numbers that showed net revenue for 4Q2023 of $11.5 million, well ahead of Zack's estimates and a more than 1300% increase from the year ago period! For the year, the company also showed preliminary net revenue of $16.7 million, which would be more than a 140% increase over 2022. The official release and the full financials, according to the company, will be released in March. See how the evidence is pointing to BioStem being one of the most exciting biotech companies underfollowed on Wall Street!This message is a PAID ADVERTISEMENT for BioStem Technologies Inc. (OTC: BSEM) from Sideways Frequency. StockEarnings, Inc receives a fixed fee for each subscriber that clicks on a link in this email, totaling up to $2,000. Other than the compensation received for this advertisement sent to subscribers, StockEarnings and its principals are not affiliated with either BioStem Technologies Inc. (OTC: BSEM) or Sideways Frequency. StockEarnings and its principals do not own any of the stocks mentioned in this email or in the article that this email links to. Neither StockEarnings nor its principals are FINRA-registered broker-dealers or investment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from StockEarnings to buy or sell any security. StockEarnings has not evaluated the accuracy of any claims made in this advertisement. StockEarnings recommends that investors do their own independent research and consult with a qualified investment professional before buying or selling any security. Investing is inherently risky. Past-performance is not indicative of future results. Please see the disclaimer regarding BioStem Technologies Inc. (OTC: BSEM) on Huge Alerts website for additional information about the relationship between Sideways Frequency and BioStem Technologies Inc. (OTC: BSEM). Your privacy is very important to us, if you wish to be excluded from future notices, do not reply to this message. Instead, please click Unsubscribe. StockEarnings, Inc |
Today's Bonus Content: Jeff Bezos backs tiny biotech with $130 mil investment
没有评论:
发表评论